• Next in Cloud: DaaS, MaaS, DRaaS

    ReadWrite | Cloud spending is only set to increase in 2013, and according to Gartner, offerings will become more specialized. The company predicts Desktop-as-a-Service (DaaS), Metal-as-a-Service (MaaS) and DisasterRecovery-as-a-Service (DRaaS) to lead the new product market in 2013.

    Mar 29, 2013

  • Davies on Bioinformatics, Genomics

    MendelsPod | Bio-IT World’s own Kevin Davies, editor-in-chief, shares his thoughts on bioinformatics. This last year has seen a flowering of new companies offering genome interpretation and reporting, but what will success for these early entrants look like?

    Mar 28, 2013

  • Canadian Scientist Declines Gairdner Award

    The Scientist | Michael Houghton, a Canadian microbiologist and immunologist, declined the prestigious Gairdner International Award because he said two colleagues were also deserving of the prize.

    Mar 28, 2013

  • IT's Role Combating the Alien Invader

    Bio-IT World Video | At the Bio-IT World Expo last year, an all star panel took on the challenges of combating cancer and “characterizing the alien invader”. Our opportunities in cancer therapies are driven by the availability of data, the panel contented, and our challenges lie in integrating the data. On the eve of the 2013 event, we evaluate our progress.

    Mar 28, 2013

  • Small Data Centers Move to the Cloud

    ComputerWorld | Day is waning for small in-house data centers, says ComputerWorld. Large firms have been consolidating data centers for a while now, but the trend is now trickling down to smaller groups.

    Mar 28, 2013

  • The Newest 'Ome' for Sequencing Studies: the Squishome

    GigaScience | Ready for the next frontier of NGS research? Bug guts. Today in GigaScience, researchers publish a "squishomics" approach to studying biodiversity.

    Mar 27, 2013

  • Privacy Debates Over HeLa Cell Sequence

    ScienceInsider | A debate has been raging over the ethics of sequencing the HeLa cell line without the consent of Henrietta Lacks' family, and many in the community have weighed in.

    Mar 26, 2013

  • Nimbus Releases New Flash Storage Software

    SemiAccurate | Nimbus Data released a software suite--Halo 2013--for their flash storage offerings. The software is a free update for existing customers and brings an analysis system, API, and mobile monitoring suite.

    Mar 26, 2013

  • Systems Biology Initiative Plans Computer-Simulated Skin Model

    News Brief | Bio-Modeling Systems (BMSystems) of France and Persistent Systems of India are launching a joint systems biology research and development initiative that will marry non-mathematical heuristic modeling with mathematical modeling designed to increase the success rates of drug discovery and formulation development.

    Mar 25, 2013

  • 2012 Growth Year for HPC Market

    eWeek | 2012 saw record revenues in the high-performance computer market, led by IBM and HP. Supercomputers led the growth, with a 29.3% increase in revenues.

    Mar 25, 2013

  • History of OpenStack and NASA

    ComputerWorld | The OpenStack cloud platform got IBM's vote of approval earlier this month. The technology was originally tied to NASA's Nebula project a 2008.

    Mar 25, 2013

  • IBM's Ion Current Chips

    eWeek | IBM’s scientists discovered a new way to operate chips using tiny ionic currents, which are streams of charged atoms that could mimic the event-driven way in which the human brain operates.

    Mar 22, 2013

  • Bibliogo is RSS Reader for Life Sciences

    Bio-IT World Product Brief | Looking for a Google Reader replacement? Bibliogo is an RSS reader designed specifically for science, says Reprints Desk.

    Mar 22, 2013

  • AMCG Releases Recommendations for Dealing with Sequencing Findings

    Nature | The American College of Medical Genetics and Genomics yesterday released recommendations for how genome-sequencing laboratories should report incidental findings after a doctor orders a genome sequence. It defines a minimum list of about 60 genes and 30 conditions that should be reported to the doctor as part of a patient’s care, whether the patient wants to know them or not.

    Mar 22, 2013

  • UK Biobank and Affymetrix Sign 500,000-Sample Genotyping Agreement

    Bio-IT World | UK Biobank and Affymetrix have signed a contract to genotype 500,000 DNA samples donated by UK residents as part of a prospective epidemiological study of complex diseases that are of great relevance to public health using Affymetrix’ Axiom Genotyping Solution.

    Mar 22, 2013

  • Ra Pharmaceuticals and the Pursuit of Peptide Drugs

    Bio-IT World Video | Doug Treco, president & CEO of Ra Pharmaceuticals, will be presenting at CHI’s Drug Discovery Chemistry conference in San Diego in April. He gives Bio-IT World editor Kevin Davies some insight into the world of cyclomimetics.

    Mar 22, 2013

  • AstraZeneca Cuts More Jobs; Signs $240M+ Agreement with Moderna

    Bio-IT World Roundup | Lots of news for AstraZeneca this morning. The company announced plans to cut 2300 sales and administrative jobs and plans to focus on respiratory, inflammation & autoimmunity; cardiovascular & metabolic disease; and oncology. The company also announced a major agreement with Moderna Therapeutics, starting with a $240 million upfront payment for mRNA research.

    Mar 21, 2013

  • March Product and News Briefs

    Bio-IT World | News briefs for March including updates from Ingenuity, GeneInsight, University of Auckland, and the Research Resonance Network. New products from SoftGenetics, Accelrys, Cynvenio Biosystems, SGI, PerkinElmer and more.

    Mar 21, 2013

  • Big Data Freeway in San Diego

    New York Times | Larry Smarr and his team at UC  San Diego are about to open the “Big Data freeway system” for next-gen data projects including genomic sequencing. The new network--Prism--is based on an optical switch developed by Arista Networks.

    Mar 20, 2013

  • Following the Gleevec Blueprint

    Xconomy | Blueprint Medicines has reunited the team behind Gleevec—Nick Lydon, Brian Druker, and Charles Sawyers. The startup, backed with a $40 million Series A financing from Third Rock Ventures and Fidelity Biosciences in 2011, believes now is the time for more drugs like the cancer blockbuster.

    Mar 20, 2013